Valneva Reports Positive Initial Phase 3 Safety Data in Adol

Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. Immunogenicity data for the trial are expected in November 2023. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in collaboration with Instituto Butantan, the VLA1553-321 adolescent trial is intended to su

Related Keywords

France , Canada , United States , Brazil , Juan Carlos Jaramillo , Joshua Drumm , Instituto Butantan , Drug Administration , Vp Global Communications European Investor Relations , Health Canada , Coalition For Epidemic Preparedness Innovations , European Union Horizon , European Medicines Agency , Euronext Paris , Epidemic Preparedness Innovations , Chief Medical Officer , Biologic License Application , Prescription Drug User Fee Act , Southeast Asia , Middle Income Countries , European Union , Breakthrough Therapy , Priority Review , Chikungunya Virus , Clinical Trial , Valneva , Safety Profile , Safety Data , Vaccine Candidate , Vaccine Company , Nitial Regulatory Approval ,